Safety and immunogenicity evaluation of recombinant BCG vaccine against respiratory syncytial virus in a randomized, double-blind, placebo-controlled phase I clinical trial-Reference-Cited by-同舟云学术

Safety and immunogenicity evaluation of recombinant BCG vaccine against respiratory syncytial virus in a randomized, double-blind, placebo-controlled phase I clinical trial

Published:2020-10 Issue: Volume:27 Page:100517
ISSN:2589-5370
Container-title:EClinicalMedicine
language:en
Short-container-title:EClinicalMedicine

Author:

Abarca Katia,Rey-Jurado Emma,Muñoz-Durango Natalia,Vázquez Yaneisi,Soto Jorge A.,Gálvez Nicolás M.S.^ORCID,Valdés-Ferrada Javier,Iturriaga Carolina,Urzúa Marcela,Borzutzky Arturo,Cerda Jaime,Villarroel Luis,Madrid Victoria,González Pablo A.,González-Aramundiz José V.,Bueno Susan M.,Kalergis Alexis M.^ORCID

Funder

Pontificia Universidad Católica de Chile

Publisher

Elsevier BV

Subject

General Medicine

Reference30 articles.

1. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis;Nair;Lancet,2010

2. Progress in understanding and controlling respiratory syncytial virus: Still crazy after all these years;Collins;Virus Res,2011

3. The burgeoning burden of respiratory syncytial virus among children;Breese Hall;Infect Disord – Drug Targets,2012

4. Neurologic alterations due to respiratory virus infections;Bohmwald;Front Cell Neurosci,2018

5. Innate immune components that regulate the pathogenesis and resolution of hRSV and hMPV Infections;Andrade;Viruses,2020

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunomodulatory markers and therapies for the management of infant respiratory syncytial virus infection;Expert Review of Anti-infective Therapy;2024-09-13

2. Respiratory Syncytial Virus Infection in Older Adults: An Update;Drugs & Aging;2024-05-07

3. Respiratory Syncytial Virus Vaccines: Analysis of Pre-Marketing Clinical Trials for Immunogenicity in the Population over 50 Years of Age;Vaccines;2024-03-25

4. A molecular perspective for the development of antibodies against the human respiratory syncytial virus;Antiviral Research;2024-02

5. All Eyes on the Prefusion-Stabilized F Construct, but Are We Missing the Potential of Alternative Targets for Respiratory Syncytial Virus Vaccine Design?;Vaccines;2024-01-18